Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

Phase 4

Active, not recruiting

Conditions: Ovarian Neoplasms
Peritoneal Neoplasms
Fallopian Tube Neoplasms

Interventions: Drug: Bevacizumab

First Posted Date: 2013-08-30

Last Posted Date: 2024-12-30

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 100

Registration Number: NCT01932125

Locations: 🇮🇳
Rajiv Gandhi Cancer Inst.&Research Center, New Delhi, Delhi, India
🇮🇳
Manipal Hospital, Bangalore, Karnataka, India
🇮🇳
HealthCare Global Enterprises Limited, Banglore, Karnataka, India

and more 10 locations

A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Trastuzumab - intravenous solution
Drug: Trastuzumab - subcutaneous solution
Drug: Chemotherapy

First Posted Date: 2013-08-27

Last Posted Date: 2014-09-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 2

Registration Number: NCT01928615

A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC)

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Trastuzumab

First Posted Date: 2013-08-21

Last Posted Date: 2019-09-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 102

Registration Number: NCT01926886

Locations: 🇮🇱
Soroka Medical Center; Oncology Dept, Beer Sheva, Israel
🇮🇱
Rabin MC; Davidof Center - Oncology Institute, Petach Tikva, Israel
🇧🇪
AZ Maria Middelares, Gent, Belgium

and more 20 locations

A Screening Study To Assess The Cognition Status in Healthy Volunteers

Completed

Conditions: Healthy Volunteer

First Posted Date: 2013-08-21

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 240

Registration Number: NCT01926873

A PET Study With RO5545965 in Healthy Male Volunteers

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: RO5545965

First Posted Date: 2013-08-14

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 9

Registration Number: NCT01923025

A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: Omalizumab

First Posted Date: 2013-08-14

Last Posted Date: 2017-12-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 806

Registration Number: NCT01922037

Locations: 🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
Chest Medicine Consultants, Chicago, Illinois, United States

and more 140 locations

A Retrospective, Observational Study of RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2013-08-13

Last Posted Date: 2013-08-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 77

Registration Number: NCT01921478

A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)

Completed

Conditions: Down Syndrome

First Posted Date: 2013-08-12

Last Posted Date: 2017-07-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 135

Registration Number: NCT01920633

Locations: 🇪🇸
IMIM, Human Pharmacology and Clinical Neurosciences,, Barcelona, Spain
🇺🇸
Emory University School of Medicine; Department of Human Genetics & Pediatrics, Decatur, Georgia, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 19 locations

U-Act-After: An Observational Study on Long-Term Efficacy of Tight Control RoActemra/Actemra (Tocilizumab) and/or Methotrexate in Patients With Early Rheumatoid Arthritis Who Have Participated in the U-Act-Early Study (ML22497)

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2013-08-07

Last Posted Date: 2018-05-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 226

Registration Number: NCT01918267

Locations: 🇳🇱
St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands
🇳🇱
University Medical Centre Utrecht; Reumatologie en Klinische Immunologie, Utrecht, Netherlands
🇳🇱
Maartenskliniek Woerden, Woerden, Netherlands

and more 16 locations

A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Pertuzumab
Drug: Lumretuzumab

First Posted Date: 2013-08-07

Last Posted Date: 2017-09-12

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 66

Registration Number: NCT01918254

Locations: 🇫🇷
Institut Curie; Oncologie Medicale, Paris, France
🇩🇪
Universitaetsklinikum Essen; Westdeutsches Tumorzentrum; Innere Klinik (Tumorforschung), Essen, Germany
🇪🇸
Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain

and more 10 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy